IOVA

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time.

Iovance Biotherapeutics raised its 2026 revenue outlook to $410-$420 million from $350-$370 million, driven by strong patient demand for its therapies Amtagvi and Proleukin. The stock surged 31.5% following the announcement. Amtagvi, the first FDA-approved TIL therapy for melanoma, generated $151 million in sales in H1 2026 with 54% year-over-year growth, and the company plans to expand authorized treatment centers from 100 to at least 110 by year-end.